Is FBRX or FULC more undervalued in 2026?

CirclFi compares Forte Biosciences, Inc. (FBRX) and Fulcrum Therapeutics, Inc. (FULC) using 13 institutional-grade valuation models. FBRX has a Quality of Company score of 4.1/10 while FULC scores 6.5/10.

Which is a better buy — FBRX or FULC?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do FBRX and FULC valuations compare?

FBRX at $19.07 and FULC at $6.92 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

FBRX vs FULC Valuation Comparison 2026 — Intrinsic Value Analysis

FBRX

Pharmaceutical Preparations

Forte Biosciences, Inc.

Quality

4.1

out of 10

Value Trap

SAFE

Price

$19.07

Last close

Models

9/13

Active

FULC

Pharmaceutical Preparations

Fulcrum Therapeutics, Inc.

Quality

6.5

out of 10

Value Trap

SAFE

Price

$6.92

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	FBRX Fair Value	FBRX Upside	FULC Fair Value	FULC Upside
Bayesian DCF	Intrinsic	$6.88	-63.9%	$2.10	-69.7%
Earnings Power Value	Intrinsic	$6.28	-77.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$3.39	-82.2%	$0.36	-94.5%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for FBRX vs FULC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

FBRX vs FULC — Which Stock Is More Undervalued?

FULC scores higher with a 6.5/10 quality rating vs FBRX's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Forte Biosciences, Inc. (FBRX) and Fulcrum Therapeutics, Inc. (FULC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

FBRX currently trades at $19.07 with a QOC of 4.1/10, while FULC trades at $6.92 with a QOC of 6.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).